$TCRT
Alaunos Therapeutics, Inc.

2020 Q1 Form 10-K Financial Statement

#000119312520058863 Filed on March 02, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.950M $5.820M $4.810M
YoY Change 43.37% 27.63% 11.6%
% of Gross Profit
Research & Development $12.71M $10.22M $8.641M
YoY Change 34.13% 24.63% 4.57%
% of Gross Profit
Depreciation & Amortization $140.0K $180.0K $150.0K
YoY Change 0.0% 5.88% 0.0%
% of Gross Profit
Operating Expenses $18.66M $16.04M $13.45M
YoY Change 36.99% 25.71% 6.98%
Operating Profit -$16.04M -$13.45M
YoY Change 25.65% 6.98%
Interest Expense $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $370.0K $290.0K $203.0K
YoY Change 97.86% 70.59% 35.33%
Pretax Income -$18.29M -$15.75M -$74.00M
YoY Change 36.19% 26.2% 487.77%
Income Tax
% Of Pretax Income
Net Earnings -$18.29M -$15.75M -$74.00M
YoY Change 36.15% -108.09% 296.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.43
Diluted Earnings Per Share -$0.09 -$0.09 -$0.43
COMMON SHARES
Basic Shares Outstanding 213.0M 181.0M 162.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $171.0M $79.70M $88.40M
YoY Change 232.04% 29.17% 178.86%
Cash & Equivalents $171.0M $79.74M $88.42M
Short-Term Investments
Other Short-Term Assets $19.80M $22.40M $23.70M
YoY Change -9.17% 8.21% 64.58%
Inventory
Prepaid Expenses
Receivables $800.0K $3.300M $3.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $191.6M $105.5M $115.6M
YoY Change 158.59% 25.16% 145.12%
LONG-TERM ASSETS
Property, Plant & Equipment $5.900M $1.110M $828.0K
YoY Change 510.13% 1.19% -38.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $110.0K $109.0K
YoY Change -88.1% -98.85% -99.4%
Total Long-Term Assets $6.700M $3.622M $2.350M
YoY Change -28.8% -66.36% -88.03%
TOTAL ASSETS
Total Short-Term Assets $191.6M $105.5M $115.6M
Total Long-Term Assets $6.700M $3.622M $2.350M
Total Assets $198.3M $109.1M $117.9M
YoY Change 137.48% 14.8% 76.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $906.0K $926.0K
YoY Change -53.43% 28.15% -27.03%
Accrued Expenses $16.20M $10.85M $9.573M
YoY Change 136.98% 23.77% 2.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.60M $12.53M $11.18M
YoY Change 99.06% 32.09% -81.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.400M $1.600M $600.0K
YoY Change 55.56% -76.92%
Total Long-Term Liabilities $1.400M $1.600M $600.0K
YoY Change 55.56% -76.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.60M $12.53M $11.18M
Total Long-Term Liabilities $1.400M $1.600M $600.0K
Total Liabilities $17.90M $14.10M $11.82M
YoY Change 92.74% 48.67% -81.17%
SHAREHOLDERS EQUITY
Retained Earnings -$684.1M -$668.4M
YoY Change 20.8% -12.2%
Common Stock $779.1M $774.5M
YoY Change 19.52% 28.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $180.3M $95.01M $106.1M
YoY Change
Total Liabilities & Shareholders Equity $198.3M $109.1M $117.9M
YoY Change 137.48% 14.8% 76.57%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$18.29M -$15.75M -$74.00M
YoY Change 36.15% -108.09% 296.57%
Depreciation, Depletion And Amortization $140.0K $180.0K $150.0K
YoY Change 0.0% 5.88% 0.0%
Cash From Operating Activities -$9.910M -$11.60M -$10.93M
YoY Change -3.15% -1.86% 28.44%
INVESTING ACTIVITIES
Capital Expenditures $510.0K $100.0K $100.0K
YoY Change 5000.0% -211.11% -41.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$510.0K -$100.0K -$100.0K
YoY Change 5000.0% -211.11% -41.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 101.7M 3.030M 55.89M
YoY Change -92.67%
NET CHANGE
Cash From Operating Activities -9.910M -11.60M -10.93M
Cash From Investing Activities -510.0K -100.0K -100.0K
Cash From Financing Activities 101.7M 3.030M 55.89M
Net Change In Cash 91.26M -8.670M 44.86M
YoY Change -991.04% -129.27% -616.82%
FREE CASH FLOW
Cash From Operating Activities -$9.910M -$11.60M -$10.93M
Capital Expenditures $510.0K $100.0K $100.0K
Free Cash Flow -$10.42M -$11.70M -$11.03M
YoY Change 1.74% -0.26% 27.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4261000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
CY2018 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
CY2017 ziop Effective Income Tax Rate Reconciliation Non Cash Inducement Warrant Expense
EffectiveIncomeTaxRateReconciliationNonCashInducementWarrantExpense
0.00
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
906000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10846000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8763000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
707000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
778953000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
651732000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
105492000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
84285000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79741000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61729000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
182000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
161000
CY2019Q4 us-gaap Assets
Assets
109114000
CY2018Q4 us-gaap Assets
Assets
95051000
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2019Q4 us-gaap Liabilities
Liabilities
14104000
CY2018Q4 us-gaap Liabilities
Liabilities
9487000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109114000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95051000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
13000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12526000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9483000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
110000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9541000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22421000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20692000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3330000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1864000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-684125000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-566329000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
95010000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
85564000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
774000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1578000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
813000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
631000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-117796000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53117000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-57858000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-53906000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
465000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-53493000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38331000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34134000
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
16998000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-54323000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19527000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19918000
CY2019 us-gaap Operating Expenses
OperatingExpenses
57858000
CY2018 us-gaap Operating Expenses
OperatingExpenses
54052000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45084000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14798000
CY2017 us-gaap Operating Expenses
OperatingExpenses
59882000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
158000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-117796000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73261000
CY2019 ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
60751000
CY2019 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1466000
CY2018 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1845000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1729000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1263000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-9431000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3942000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
199000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3709000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1725000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1145000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-146000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-125000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61729000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71334000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79741000
CY2019 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
284000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
459000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-284000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-459000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40854000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49457000
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1622000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1219000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
653000
CY2019 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7341000
CY2018 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7534000
CY2019 ziop Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
-2000
CY2019 ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
60751000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
52499000
CY2018 ziop Related Party Transaction Expenses From Transactions With Related Party Advisory Fees
RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
2000000
CY2019Q1 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
2000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
772000
CY2019 us-gaap Lease Cost
LeaseCost
772000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
723000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
736000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
488000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1947000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2017 ziop License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2272000
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3992000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12991000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
800000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6389000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-139000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81441000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
737000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-737000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54669000
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000
CY2017 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
8454000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45299000
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
212999979
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Trading Symbol
TradingSymbol
ZIOP
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
181803320
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161066136
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181803320
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161066136
CY2019Q2 dei Entity Public Float
EntityPublicFloat
834869811
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6389000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1295000
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18938000
CY2018 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
207361000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7534000
CY2017 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2059000
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
18938000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47270000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-77298000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8454000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000
CY2018 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1624000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47101000
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
16998000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6341000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1219000
CY2019 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
653000
CY2019 ziop Stock Issued During Period Value Net On Exercise Of Warrants
StockIssuedDuringPeriodValueNetOnExerciseOfWarrants
60751000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6085000
CY2019 ziop Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
52499000
CY2018 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
207361000
CY2019 ziop Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
63000
CY2017 ziop Payment For Issuance Of Restricted Common Stock
PaymentForIssuanceOfRestrictedCommonStock
2059000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
CY2018 ziop Proceeds From Underwritten Financing
ProceedsFromUnderwrittenFinancing
47101000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6085000
CY2018 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-5408000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59150000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40311000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18012000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9605000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10107000
CY2019 ziop Payment Of Bonusin Common Stock
PaymentOfBonusinCommonStock
1000000
CY2019 ziop Fixed Assets In Accrued Expenses
FixedAssetsInAccruedExpenses
358000
CY2018 ziop Related Party Transaction Amounts Of Non Cash Transaction
RelatedPartyTransactionAmountsOfNonCashTransaction
212769000
CY2019 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2814673
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9708738
CY2017Q2 ziop Public Offering Net Price Per Share
PublicOfferingNetPricePerShare
5.15
CY2017Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.893
CY2017Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
47300000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40295218
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7139
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70946000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
388000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35139000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-712442000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
137246000
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6341000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
7534000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8454000
CY2019 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
6341000
CY2018 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
7534000
CY2017 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
8454000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0139
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0253
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8500
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0255
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0306
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8075
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8471
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0185
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0227
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8031
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8103
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
167952114
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143508674
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136938264
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
201362
CY2018 ziop Incremental Common Shares Attributable To Dilutive Effect Of Nonvested Restricted Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfNonvestedRestrictedCommonShares
124
CY2018 ziop Dilutive Potential Common Shares
DilutivePotentialCommonShares
201486
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167952114
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143710160
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136938264
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30085242
CY2019Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
5247000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.01
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24697063
CY2018Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
3003000
CY2019Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1910000
CY2018Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1786000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
194538000
CY2017 us-gaap Depreciation
Depreciation
369000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.64
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.94
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
57500000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.47
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5942000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5300000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4832000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4203000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1110000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1097000
CY2019 us-gaap Depreciation
Depreciation
629000
CY2018 us-gaap Depreciation
Depreciation
575000
CY2019Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
1147000
CY2018Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
1247000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
991000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
745000
CY2019Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
586000
CY2018Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
1164000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
489000
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
363000
CY2019Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
284000
CY2018Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
349000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
192000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2019Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
100000
CY2018Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1000000
CY2018 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
223000
CY2018 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.01
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
925000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
701000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
213000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
220000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
226000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
514000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2799000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
447000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2352000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1200000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
106430000
CY2019Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
30480000
CY2018Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
33977000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
33684000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1087000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
990000
CY2019Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
4501000
CY2018Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
5160000
CY2019Q4 ziop Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
626000
CY2019Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
176000
CY2018Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
132000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1186000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
920000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
181293000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
605000
CY2019Q4 ziop Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
605000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
605000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04
CY2019 ziop Effective Income Tax Rate Reconciliation Non Cash Inducement Warrant Expense
EffectiveIncomeTaxRateReconciliationNonCashInducementWarrantExpense
-0.11
CY2018 ziop Effective Income Tax Rate Reconciliation Non Cash Inducement Warrant Expense
EffectiveIncomeTaxRateReconciliationNonCashInducementWarrantExpense
0.00
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.02
CY2006Q2 ziop Shares Authorized
SharesAuthorized
280000000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2006Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
0.00
CY2017 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.02
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2019 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
0.00
CY2018 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
0.00
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
-0.07
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.02
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2019 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
0.00
CY2018 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
0.03
CY2017 ziop Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
-1.24
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.13
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.96
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2019 ziop Operating Loss Carryforwards Research Expiration Dates
OperatingLossCarryforwardsResearchExpirationDates
2039
CY2017 us-gaap Revenues
Revenues
15900000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
41500000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15400000
CY2019 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2018 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2006Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2006Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
18939394
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.64
CY2018Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
47100000
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
862000
CY2017 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
267000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1295000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2424000
CY2019 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
0
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
158000
CY2018Q4 ziop Preferred Stock Redemption Discount Derivatives
PreferredStockRedemptionDiscountDerivatives
-2489000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12762000
CY2018Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5120000
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5462000
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6074000
CY2018Q4 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
342000
CY2018Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
207361000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-21140000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-17493000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13621000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14753000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13448000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-16036000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13434000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14620000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-73996000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-15746000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-18659000
CY2019 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
404000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
329000
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
90000
CY2019Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
13621000
CY2019Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14753000
CY2019Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
13448000
CY2019Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
16036000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
CY2018Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
16342000
CY2018Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12378000
CY2018Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12570000
CY2018Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12762000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16196000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12378000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12570000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.29
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.29
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3465335
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
688800
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.27
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
180000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.67
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
122000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.64
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852135
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1744950
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.35
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
104167
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.30
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
215833
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.72
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5277085
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.24
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2880691
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.40
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
581105
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.30
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1733792
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.21
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5842879
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y25D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7482000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2765357
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3603000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3099935
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.15
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M4D
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
88000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2503508
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.39
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5842879
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2018 ziop Common Stock Issuance Cost
CommonStockIssuanceCost
2898000
CY2017 ziop Common Stock Issuance Cost
CommonStockIssuanceCost
2700000
CY2019Q3 ziop Non Operating Income Expense Inducement Of Warrants
NonOperatingIncomeExpenseInducementOfWarrants
-60751000
CY2018Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 ziop Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
0
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
128000000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y5M1D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1038
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;;width:1%;">&#160;</td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Clinical trial expenses; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;;width:1%;">&#160;</td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Collaboration agreements; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;;width:1%;">&#160;</td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements of stock-based compensation and Series 1 preferred stock (and related dividends); and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;;width:1%;">&#160;</td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Income taxes. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
124115000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
35130000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
196696000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
197301000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
181293000

Files In Submission

Name View Source Status
0001193125-20-058863-index-headers.html Edgar Link pending
0001193125-20-058863-index.html Edgar Link pending
0001193125-20-058863.txt Edgar Link pending
0001193125-20-058863-xbrl.zip Edgar Link pending
d861766d10k.htm Edgar Link pending
d861766dex1020.htm Edgar Link pending
d861766dex1021.htm Edgar Link pending
d861766dex1023.htm Edgar Link pending
d861766dex211.htm Edgar Link pending
d861766dex231.htm Edgar Link pending
d861766dex311.htm Edgar Link pending
d861766dex312.htm Edgar Link pending
d861766dex321.htm Edgar Link pending
d861766dex322.htm Edgar Link pending
d861766dex47.htm Edgar Link pending
d861766dex48.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g861766g02a00.jpg Edgar Link pending
g861766g06a42.jpg Edgar Link pending
g861766g08a50.jpg Edgar Link pending
g861766g10b64.jpg Edgar Link pending
g861766g12s02.jpg Edgar Link pending
g861766g17z08.jpg Edgar Link pending
g861766g20s09.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20191231.xml Edgar Link completed
ziop-20191231.xsd Edgar Link pending
ziop-20191231_cal.xml Edgar Link unprocessable
ziop-20191231_def.xml Edgar Link unprocessable
ziop-20191231_lab.xml Edgar Link unprocessable
ziop-20191231_pre.xml Edgar Link unprocessable